Full antagonism of the estrogen receptor without a prototypical ligand side chain.
Srinivasan, S., Nwachukwu, J.C., Bruno, N.E., Dharmarajan, V., Goswami, D., Kastrati, I., Novick, S., Nowak, J., Cavett, V., Zhou, H.B., Boonmuen, N., Zhao, Y., Min, J., Frasor, J., Katzenellenbogen, B.S., Griffin, P.R., Katzenellenbogen, J.A., Nettles, K.W.(2017) Nat Chem Biol 13: 111-118
- PubMed: 27870835 
- DOI: 10.1038/nchembio.2236
- Primary Citation of Related Structures:  
5KCC, 5KCD, 5KCE, 5KCF, 5KCT, 5KCU, 5KCW, 5KD9 - PubMed Abstract: 
Resistance to endocrine therapies remains a major clinical problem for the treatment of estrogen receptor-α (ERα)-positive breast cancer. On-target side effects limit therapeutic compliance and use for chemoprevention, highlighting an unmet need for new therapies ...